- Lexaria, a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study
- The study was made up of three main groups of formulations: DehydraTECH-processed CBD; semaglutide (including “Rybelsus(R)”) and liraglutide
- The DehydraTECH-CBD and DehydraTECH-liraglutide both outperformed Rybelsus(R), which was a surprise outcome. DehydraTECH-liraglutide posted a weight reduction of 4.74%, the most significant in the study
- For Lexaria, this continued outperformance of DehydraTECH-liraglutide is of particular interest, particularly since many third-party studies have shown semaglutide to be more than twice as effective as liraglutide in promoting weight loss
- As the study progresses, Lexaria’s management is optimistic that it will realize positive and ground-breaking results that will demonstrate the superiority and potential of its technology
Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study. This study explores Lexaria’s patented technology, DehydraTECH(TM), and its potential in addressing diabetes and weight loss. More importantly, it looks to establish whether DehdyraTECH processing results in higher brain absorption than non-DehydraTECH arms, with a focus on glucagon-like peptide 1 (“GLP-1”) drugs, liraglutide and semaglutide (https://nnw.fm/Xksm8).
This part of the study was comprised of eight different formulation arms. Arms A through D used different DehydraTECH-CBD compositions, with arms E and F using DehydratTECH-processed Rybelsus, and arms G and H using pure GLP-1 drugs (semaglutide and liraglutide, respectively) processed with DehydraTECH. At the eight-week mark, the liraglutide arm H posted a weight reduction of 4.74%, the most significant weight reduction from the entire study. Equally interesting, two of the DehydraTECH-CBD compositions also led to weight reductions and also outperformed both Rybelsus(R) and pure semaglutide (https://nnw.fm/Xksm8).
For Lexaria, this continued outperformance of DehydraTECH-liraglutide and DehydraTECH-CBD is of particular interest. Lexaria fully owns DehydraTECH-CBD, while liraglutide has become available in generic version. This presents a massive opportunity for Lexaria and its goal of offering a potential treatment option for diabetes and weight loss.
The global diabetes drugs market in 2023 was valued at $79.925 billion. By 2032, it is projected to hit $153.98 billion in value, representing a CAGR of 7% over the forecast period (2024-2032) (https://nnw.fm/c3KCM). Lexaria looks to carve out a decent market share from this growth with its DehydraTECH technology, primarily by offering a viable oral treatment alternative to what is currently in the market. Its DehydraTECH technology has proven itself many times to improve drug delivery, and it has also done so in its ongoing studies. The company looks to build on this, ultimately offering an oral alternative to diabetes treatment.
As the study progresses, Lexaria’s management is optimistic that it will realize positive and ground-breaking results that will demonstrate the superiority and potential of its technology. They are also confident that results from the study will inch the company closer to carving out a market share in the diabetes and obesity treatment market, even as it continues to create value for its shareholders.
For company information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is powered by IBN
